All Type of News
Pro and con over NHI financial integration issue
The political circle is in endless debates on the NHI financial integration issue. The GNP opposition party tried to keep holding over the NHI financial integration issue raised by the government and the ruling MDP in...
HIRA to regulate high-priced drugs
The Health Insurance Review Agency (HIRA) said at a meeting with parliamentary committee of health and welfare on April 21 that the agency will push to discourage the use of high-priced prescription drugs in the medic...
Relative benefit criteria for low-priced essential drugs questioned
Pharmaceutical business sources say that although the health ministry recently selected more 300 generics for cost compensation, the list of 400 essential drugs, which has selected by the government from April 2000, h...
KFDA to boost pharmaceutical export.
Before the end of this year 200 key export drug items will be selected under the incentive plans such as tax and other provisional benefits.
The KFDA took the lst meeting of the Pharmaceutical Export Supporting Ce...
Multinational drug firms post brisk sales
Foreign drug manufacturers in the local market have been on the receiving end of a sales bonanza since medical reforms were instituted three years ago, whereas Korean drug manufacturers are on edge.
Rep. Ki...
Incentive plans for any drugs proven of its efficacy equivalency.
The KFDA will provide an incentive plan for any drugs that were already proved its efficacy equivalencies to the original products through not only the bio-equivalent test but also other physicochemical test or compar...
SARS tests needs to be clarified in parliamentary hearing
In line with the recent report of the National Institute of Health that is confusing the nation over the result of its tests on severe acute respiratory syndrome (SARS), Rep. Kim Hong-shin of the parliamentary committ...
AstraZeneca headquarters selects Korea as one of most attracting investment countries
AstraZeneca Korea announced recently that Andrew Hauden, vice-president of AstraZeneca's Asia and Pacific regions, is slated to visit his third-time visit to Korea on April 21 following the previous visit of executive...
M&A rumor in pharmacy franchise business circles.
Amid the bi-polar phenomenon, the poor and the rich, being widely prevailed in the pharmacy franchise industrial markets, an M&A rumor seems to be surfaced. After the medical and pharmacy role separation program settl...
Pfizer Korea to focus on arthritis drugs as moneymaker
With Pfizer and Pharmacia combining operations on April 16, Pfizer Korea seems like to concentrate its sales on Bextra, Celebrex and Xalatan as new cash cow in the current downturn in the domestic pharmaceutical indus...
